Edition:
United Kingdom

Krystal Biotech Inc (KRYS.OQ)

KRYS.OQ on NASDAQ Stock Exchange Capital Market

17.86USD
8:37pm BST
Change (% chg)

$0.36 (+2.06%)
Prev Close
$17.50
Open
$17.57
Day's High
$17.89
Day's Low
$17.50
Volume
19,805
Avg. Vol
7,130
52-wk High
$17.89
52-wk Low
$8.03

Latest Key Developments (Source: Significant Developments)

Krystal Biotech Q1 Loss Per Share $0.21
Monday, 7 May 2018 

Krystal Biotech Inc ::KRYSTAL BIOTECH REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.21.KRYSTAL BIOTECH - CASH AND CASH EQUIVALENTS TOTALED $47.2 MILLION AT MARCH 31, 2018, COMPARED WITH $49.6 MILLION AT DEC 31, 2017.  Full Article

Krystal Biotech Announces FDA Clearance Of IND On KB103 For The Treatment Of Dystrophic Epidermolysis Bullosa
Thursday, 26 Apr 2018 

April 26 (Reuters) - Krystal Biotech Inc ::KRYSTAL BIOTECH ANNOUNCES FDA CLEARANCE OF IND ON KB103 TO BEGIN ENROLLING PATIENTS FOR THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA.KRYSTAL BIOTECH INC - PLANNED PHASE 1/2 CLINICAL STUDY OF KB103 IS A SINGLE SITE STUDY AT STANFORD UNIVERSITY EXPECTED TO START IN MAY 2018.KRYSTAL BIOTECH INC - INITIAL DATA FROM STUDY OF KB103 ARE EXPECTED TO BE RELEASED BY END OF 2018.  Full Article

Krystal Biotech reports qtrly loss per share $1.26‍​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Krystal Biotech Inc :Krystal Biotech reports that KB103 received clearance from RAC review and announces third quarter 2017 financial results.Krystal Biotech Inc qtrly loss per share $1.26‍​.Krystal Biotech Inc - ‍Currently preparing to file an investigational drug application for KB103 in Q1 of 2018​.  Full Article

Krystal Biotech says KB103 granted orphan drug designation by FDA
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Krystal Biotech Inc :Krystal Biotech’s KB103 granted orphan drug designation by the FDA to treat patients with dystrophic epidermolysis bullosa.Krystal Biotech Inc - on track to file IND for KB103 in Q1 2018​.  Full Article

BRIEF-U.S. FDA Grants Fast Track Designation For Krystal Biotech’S Kb103

* U.S. FDA GRANTS FAST TRACK DESIGNATION FOR KRYSTAL BIOTECH’S KB103 FOR THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)